Dr. Craig Towers' research on treating pregnant women with opioid addiction was celebrated across medical circles and in major media outlets, including an interview with CNN's Dr. Sanjay Gupta who described outcomes as "miracles." The Knoxville News Sentinel honored Towers as a "Health Care Hero" for his work at the University of Tennessee Medical Center. His study, published in 2020, challenged conventional medical doctrine by suggesting that pregnant patients could be safely detoxed from opioid replacement therapies rather than maintained on methadone or buprenorphine throughout pregnancy.
The study enrolled 230 participants, with 121 taking naltrexone, a non-opioid medication that blocks the high from drug use. Towers argued this approach resulted in fewer infants born experiencing withdrawal symptoms. The research prompted clinics across Tennessee and in Daytona Beach, Florida to adopt his methods. In 2019, the medical school granted additional funding for his work, praising "his many research efforts and leadership that has resulted in national recognition."
What the Right Is Saying
Medical professionals in conservative-leaning regions defended Towers' work, noting the urgent need for solutions to a devastating crisis. The opioid epidemic hit Tennessee's Appalachian communities particularly hard, with high rates of infants born experiencing neonatal abstinence syndrome. Practitioners who adopted Towers' approach argued they were responding to a genuine emergency and that his methods showed promise for reducing newborn withdrawal symptoms in their patient populations.
Some medical commentators have noted that the audit findings, while serious, relate primarily to administrative compliance rather than the underlying clinical data. They argue that research oversight should be strengthened without creating regulatory barriers so burdensome that physicians stop attempting to address urgent public health crises. Supporters of the approach have emphasized that Tennessee clinicians faced an unprecedented situation and were trying to help mothers and babies.
What the Left Is Saying
Progressive health policy advocates and addiction specialists raised concerns about patient safety from the moment Towers' findings circulated. Dr. Mishka Terplan, a board-certified OB-GYN specializing in addiction medicine who has helped develop federal treatment guidelines, wrote to the University of Tennessee in July 2020 expressing alarm. "Dr. Towers' work has been impactful, especially in TN," Terplan stated, "and I am concerned that each day the article(s) is out there, potential harm to a vulnerable population accumulates through both ethically suspect clinical care and consequently misguided public health."
Eight specialists in addiction treatment and pregnancy collaborated on a letter to university administrators outlining their concerns. They noted that naltrexone had shown lackluster results in other major studies, with relapse rates averaging 72% among nonpregnant patients according to a systematic review of 13 studies. Advocates for pregnant women with substance use disorders argue that research involving vulnerable populations requires heightened scrutiny and that the potential for well-intentioned but flawed science to reshape clinical practice poses serious risks.
What the Numbers Show
A university audit conducted after concerns were raised found multiple compliance failures: Towers failed to obtain proper university approval for the study, provided "inaccurate and/or unverifiable, contradictory source documentation" for a study component, did not supply research databases or data analysis when requested, and auditors could not determine the extent to which patient health information was protected. The journal that published the study issued a 78-word correction in 2023 acknowledging the work had been improperly listed as "prospective," a designation indicating rigorous real-time patient tracking.
In other major studies, naltrexone has shown relapse rates averaging 72% among nonpregnant patients, according to a systematic review of 13 studies cited by specialists. The original study enrolled 230 participants, with 121 receiving naltrexone treatment. Federal guidelines from professional medical organizations have historically recommended maintaining patients on methadone or buprenorphine during pregnancy due to concerns about withdrawal risks.
The Bottom Line
The case highlights questions about research oversight at academic medical centers and the speed at which clinical practices can shift based on influential studies. Professional addiction medicine organizations continue to recommend maintenance therapy with methadone or buprenorphine for pregnant patients, though individual practitioners may have adopted Towers' approach. The University of Tennessee has not publicly disclosed what disciplinary actions, if any, resulted from the audit findings. Watch for whether other institutions that adopted his methods revise their protocols and whether federal research oversight bodies issue guidance on protecting vulnerable populations in clinical studies.